{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:00:21Z","timestamp":1791136821657,"version":"4.1.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009060","name":"Sidaction","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0152952","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T14:56:31Z","timestamp":1461855391000},"page":"e0152952","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy"],"prefix":"10.1371","volume":"11","author":[{"given":"Edouard","family":"Lhomme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Pasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros A.","family":"Kalams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"issue":"4599","key":"ref1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"F Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"ref2","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: 2013."},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"9653","key":"ref4","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"NM Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"GE Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"ref7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy Trial of a DNA\/rAd5 HIV-1 Preventive Vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"P Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/infdis\/jiq152","article-title":"Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials","volume":"203","author":"PB Gilbert","year":"2011","journal-title":"J Infect Dis"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vC1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"ML Robb","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1413","article-title":"Helping the CD8+ T-cell response","volume":"4","author":"MJ Bevan","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"RA Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1080\/21645515.2015.1011974","article-title":"Recent developments in clinical trial designs for HIV vaccine research","volume":"11","author":"L Richert","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1086\/655652","article-title":"T cell immunity in acute HIV-1 infection","volume":"202","author":"H Streeck","year":"2010","journal-title":"J Infect Dis"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.coviro.2013.05.009","article-title":"The role of T cell immunity in HIV-1 infection","volume":"3","author":"CM Ling Munier","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"4","key":"ref16","first-page":"333","article-title":"Immune response to HIV","volume":"8","author":"M Perreau","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.1101421","article-title":"HIV-DNA priming alters T-cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable","volume":"187","author":"SC De Rosa","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and Validation of an 8-Color Intracellular Cytokine Staining (ICS) Assay to Quantify Antigen-Specific T Cells Induced by Vaccination","volume":"323","author":"H Horton","year":"2007","journal-title":"J Immunol Methods"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2006.07.050","article-title":"NIAID HIV Vaccine Trials Network. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers","volume":"25","author":"PA Goepfert","year":"2007","journal-title":"Vaccine"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2012.10.021","article-title":"Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults","volume":"38","author":"LF Su","year":"2013","journal-title":"Immunity"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3102\/10769986025001060","article-title":"On the Adaptive Control of the False Discovery Rate in Multiple Testing with Independent Statistics","volume":"25","author":"Y Benjamini","year":"2000","journal-title":"J Educ Behav Stat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1016\/j.csda.2006.05.021","article-title":"Robustness of the linear mixed model to misspecified error distribution","volume":"51","author":"H Jacqmin-Gadda","year":"2007","journal-title":"Computational Statistics and Data Analysis"},{"key":"ref23","author":"G Verbeke","year":"2000"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","article-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"FE Harrell","year":"2001"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/978-1-4419-6451-9_3","article-title":"The role of interleukin-2 in memory CD8 cell differentiation","volume":"684","author":"O Boyman","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"O Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"e7766","DOI":"10.1371\/journal.pone.0007766","article-title":"CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses","volume":"4","author":"YP Lai","year":"2009","journal-title":"PLoS One"},{"issue":"46","key":"ref28","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1016\/j.vaccine.2011.08.098","article-title":"Safety and immunogenicity of a modified pox vector-based HIV\/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)","volume":"29","author":"F Garc\u00eda","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"e29231","DOI":"10.1371\/journal.pone.0029231","article-title":"NIAID HIV Vaccine Trials Network. Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and\/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults","volume":"7","author":"SA Kalams","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/CVI.00450-14","article-title":"Phase I\/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime\/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants","volume":"21","author":"SE Frey","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1371\/journal.pone.0013983","article-title":"Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate","volume":"5","author":"JR Currier","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.180.3.1517","article-title":"Kinetic and mechanistic requirements for helping CD8 T cells","volume":"180","author":"P Agnellini","year":"2008","journal-title":"J Immunol"},{"issue":"20","key":"ref33","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.vaccine.2015.03.036","article-title":"Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials","volume":"33","author":"X Jin","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"SA Kalams","year":"2013","journal-title":"J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0152952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T23:34:04Z","timestamp":1567812844000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0152952"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,28]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0152952","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,28]]}}}